the webinar will be announced in the **Federal Register**.

Request for Nomination of Speakers: The ORoC invites nominations of speakers for the webinar with expertise in exposure assessment, industrial hygiene, cancer epidemiology, or lymphohematopoietic cancers and knowledge of cancer studies on exposure to TCE. Self nomination is permitted. Each nomination should include (1) contact information for the nominee [name, affiliation (if any), address, telephone, and email], (2) a short description of the individual's expertise relative to topics covered above in ''Information on Proposed Webinar,'' and (3) current curriculum vitae. Nominations of experts can be submitted on-line via the TCE candidate substance Web page (*http://ntp.niehs.nih.gov/go/37899*) or by email to *lunn@niehs.nih.gov;* receipt will be acknowledged by email. Persons submitting nominations on-line or by email should provide their name, contact information, affiliation, and sponsoring organization (if any). The deadline for nominations is December 9, 2013. Persons selected as speakers will be notified by email at least 30 days prior to the webinar.

Responses to this request for nominations are voluntary. This request for nominations is for planning purposes only. Please note that the U.S. Government will not pay for the preparation of any information submitted, and no proprietary, classified, confidential, or sensitive information should be included in the submission.

Background Information on TCE: TCE, a volatile chlorinated alkene used mainly as a metal cleaner and degreaser, has been listed in the RoC as *reasonably anticipated to be a human carcinogen* since 2000 (*http://ntp-server.niehs.nih.gov/ntp/roc/twelfth/profiles/Trichloroethylene.pdf*). The NTP selected TCE for evaluation to determine whether a change in its listing status in the RoC might be warranted because of the extensive database of recent cancer studies on TCE and the public health concern due to its pervasiveness in the environment and its presence in food, numerous consumer products, and the workplace. Additional information on the status of the RoC review of TCE is available at *http://ntp.niehs.nih.gov/go/37899.*

Background Information on the RoC: The RoC is a congressionally mandated, science-based, public health report that identifies agents, substances, mixtures, or exposures (collectively called ''substances'') in our environment that pose a cancer hazard for people in the United States. The NTP prepares the RoC, on behalf of the Secretary of Health and Human Services, using a four-part process and established criteria (*http://ntp.niehs.nih.gov/go/rocprocess*). Published biennially, each edition of the RoC is cumulative and consists of substances newly reviewed in addition to those listed in previous editions. The 12th RoC, the latest edition, was published on June 10, 2011 (available at *http://ntp.niehs.nih.gov/go/roc12*). The 13th RoC is under development.

Dated: November 5, 2013.

John R. Bucher,

Associate Director, National Toxicology Program.

[FR Doc. 2013–26909 Filed 11–8–13; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel, October 22, 2013, 08:00 a.m. to October 22, 2013, 04:00 p.m., Hotel Kabuki, 1625 Post Street, San Francisco, CA, 94115 which was published in the **Federal Register** on September 10, 2013, 78 FR 55266.

The meeting will be held on November 25, 2013, 08:00 a.m. to November 25, 2013, 04:00 p.m., National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD, 20892. The meeting is closed to the public.

Dated: *November 5, 2013.*

David Clary,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013–26898 Filed 11–8–13; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Cancer Genetics Study Section, October 10, 2013, 08:00 a.m. to October 10, 2013, 06:30 p.m., Renaissance Arlington Capital View Hotel, 2800 South Potomac Ave, Arlington, VA, 22202 which was published in the **Federal Register** on September 11, 2013, 78 FR 176 Pgs. 55752–55753.

The meeting will be held at the Embassy Suites Chevy Chase, 4300 Military Rd. NW., Washington, DC 20015. The meeting will start on January 10, 2014 at 8:00 a.m. and end January 10, 2014 at 6:00 p.m. The meeting is closed to the public.

Dated: November 5, 2013.

Michelle Trout,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013–26893 Filed 11–8–13; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel; NIBIB P41 NMR Meeting (2014/05).

Date: March 13–14, 2014.

Time: 4:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Two Democracy Plaza, Suite 920, 6707 Democracy Boulevard, Bethesda, MD 20892, (Virtual Meeting).

Contact Person: Ruth Grossman, DDS, Scientific Review Officer, National Institute of Biomedical Imaging and Bioengineering, 6707 Democracy Boulevard, Room 960, Bethesda, MD 20892, 301–496–8775, *grossmanrs@mail.nih.gov.*

Dated: November 5, 2013.

David Clary,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013–26903 Filed 11–8–13; 8:45 am]

BILLING CODE 4140–01–P